RE-BVS – Piemonte Repository

Sfoglia per AUTORE
THIEBLEMONT C
Collezione ASL Biella

Items : 5

Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy in Blood

2024
ASL Biella

Bommier C; Zucca E; Chevret S; Conconi A; Nowakowski G; Maurer MJ; Cerhan JR; Thieblemont C; Lambert J;

Time to Complete Response within 24 Months As a Good Surrogate Marker of 8 Year-Progression Free Survival in Extranodal Marginal Zone Lymphoma in Blood

2022
ASL Biella

Bommier C; Conconi A; Zucca E; Nowakowski GS; Cerhan JR; Thieblemont C; Lambert J;

Early progression of disease (POD24) predicts shorter survival in malt lymphoma patients receiving systemic treatment in Hematological Oncology

2019
ASL Biella

Conconi A; Thieblemont C; Cascione L; Torri V; Kiesewetter B; Margiotta-Casaluci G; Gaidano G; Raderer M; Cavalli F; Lopez Guillermo A; Johnson PW; Zucca E;

Early progression of disease (POD24) as survival predictor in MALT lymphoma in Journal of Clinical Oncology

2019
ASL Biella

Conconi A; Thieblemont C; Cascione L; Torri V; Kiesewetter B; Margiotta-Casaluci G; Gaidano G; Raderer M; Cavalli F; Lopez-Guillermo A; Johnson PWM; Zucca E;

IELSG-38: A phase II study of chlorambucil in combination with rituximab followed by maintenance therapy with subcutaneous rituximab in patients with extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT) in Blood

2017
ASL Biella

Stathis A; Gregorini A; Gressin R; Orsucci L; Perrot A; Tani M; Coiffier B; Musuraca G; Guieze R; Marino D; Gini G; Ferrari A; Gyan E; Morschhauser F; Palombi F; Cavallo F; Gouill SL; Tilly H; Salvi F; Conconi A; Cabras MG; Capochiani E; Califano C; Molinari AL; Pulsoni A; Ielmini N; Luminari S; Cavalli F; Zucca E; et alii...